Cometriq Kit
Product Images NDC 42388-011

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Cometriq (NDC 42388-011). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Exelixis, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton (100 mg daily dose of COMETRIQ)

Cometriq 100 mg Daily Dose blister cards packaging label for cabozantinib capsules. The carton is manufactured by Exelixis, Inc. and holds 4 blister cards with capsules equivalent to 100 mg daily dose. The label includes storage instructions and a barcode. The packaging is predominantly white with green highlights for dose information and the Exelixis logo in black.*

FDA Label Image

Carton (140 mg daily dose of COMETRIQ)

COMETRIQ 140 mg capsules packaging label for cabozantinib, a human prescription drug in kit form. The carton is labeled for 140 mg daily dose blister cards, with instructions to store between 20 to 25°C and keep out of reach of children. It is manufactured by Exelixis, Inc. The carton contains 4 blister cards for patients prescribed a 140 mg daily dose.*

FDA Label Image

Carton (60 mg daily dose of COMETRIQ)

Packaging label for COMETRIQ (cabozantinib) capsules, 60 mg daily dose blister cards. The label shows a carton containing four blister cards, each card holding three 20 mg capsules to total a 60 mg daily dose. The labeler is Exelixis, Inc., featuring their logo and product information including storage instructions and prescription-only status.*

FDA Label Image

Image Of Chemical Structure Of Cometriq (Cometriq Chem Structure)

Chemical structure of cabozantinib, the active ingredient in COMETRIQ 20 mg/1 kit by Exelixis, Inc., showing detailed molecular bonds and functional groups.*

FDA Label Image

Image Of Progression-free Survival (Cometriq Figure 01)

A Kaplan-Meier survival curve comparing progression-free survival in months for subjects treated with Cometriq (cabozantinib) versus placebo. The y-axis shows the probability of subjects who are progression-free, and the x-axis shows time in months. Two curves are displayed: a red line for Cometriq and a blue dashed line for placebo, with numbers of subjects at risk listed below the x-axis at various time points.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.